Turning Point Therapeutics

Traded on the St. Petersburg Stock Exchange
Turning Point Therapeutics is an American clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. The company was founded in 2013 and is headquartered in San Diego, California.
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Turning Point Therapeutics balance sheet

Report period2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Turning Point Therapeutics cash flows

Report period2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Turning Point Therapeutics multipliers

Report period2018 2019 2020 2021
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Turning Point Therapeutics profitability

Report period2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Turning Point Therapeutics assets
Turning Point Therapeutics cash flows

Turning Point Therapeutics dividend policy

The company doesn't provide dividends
Turning Point Therapeutics news
17.08.2022
Bristol Myers Squibb has completed its acquisition of Turning Point Therapeutics for $4.1 billion, or $76 per share.
Source: {source} pictogram news.bms.com
Pictogram next
03.06.2022
Bristol Myers Squibb will acquire Turning Point Therapeutics for $4.1 billion, or $76 per share. The deal is expected to close in Q3 2022.
Source: {source} pictogram news.bms.com
Pictogram next
11.05.2022
Turning Point Therapeutics' GAAP loss for 3 months of 2022 was $74.445 million, up 2.1 times from $35.504 million in the prior year. Revenue declined multiple times to $0.429 million from $25.205 million a year earlier.
Source: {source} pictogram ir.tptherapeutics.com
Pictogram next
01.03.2022
Turning Point Therapeutics' GAAP loss for 2021 was $236.551 million, up 50.4% from $157.292 million in the prior year. Revenue increased 23.3% to $30.829 million compared to $25 million a year earlier.
Source: {source} pictogram ir.tptherapeutics.com
Pictogram next
All Turning Point Therapeutics news
General information
Company nameTurning Point Therapeutics
Tags#biotechnology, #cancer treatment
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address10628 Science Center Drive Suite 200 San Diego, CA 92121 United States
Mailing address10628 Science Center Drive Suite 200 San Diego, CA 92121 United States
Websiteir.tptherapeutics.com